LT10430-201 THEA - Axial Myopia in Children Ages 6-12
We are currently enrolling participants for a clinical research study evaluating the Safety and Efficacy of T10430 Eye Drops in Controlling Pediatric Myopia Progression.
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.
About the Study
- This study is for children between 6 to 12 years old who have axial myopia.
- Spherical equivalent refractive error (SER) of at least -1.00D and no more than -6.00D in each eye as measured by cycloplegic autorefraction.
- Distant BCVA equal or better than 0.1 LogMAR [≤ 0.1 LogMAR (equivalent to ≥ 20/25 Snellen)] in each eye.
- The study duration is about 13 months.
Why Participate?
By joining, you may have the opportunity to access an investigational treatment not yet widely available, while also helping advance research that could benefit others with Axial Myopia in the future.
If you or your child has been diagnosed with Axial Myopia and are interested in learning more about this study, please contact our team to see if you may qualify.
